Dɛn dɔn rɛkɔmɛnd yu di Inotuzumab Ozogamicin vaysin? Lɛ wi tɔk bɔt am!

Sɔntɛnde we dɔktɔ dɛn kin bigin fɔ tek nyu mɛrɛsin, wi kin fred smɔl we wi yɛri di nem, nɔto so? Ɛn na so i bi wit dis mɛrɛsin we dɛn kɔl Inotuzumab Ozogamicin. Na rili spɛshal mɛrɛsin, we dɛn kin yuz fɔ trit wan kayn blɔd kansa we dɛn kɔl Acute Lymphoblastic Leukemia (ALL). So, lɛ wi tɔk smɔl bɔt dis mɛrɛsin, wetin i de du to yu bɔdi, ɛn us tin dɛn wi nid fɔ no bɔt? Nɔ wɔri, wi go ɛksplen ɔltin di we we yu go ɔndastand.

Us kayn mɛrɛsin na Inotuzumab Ozogamicin?

Fɔs, lɛ wi si wetin na dis mɛrɛsin. Inotuzumab Ozogamicin na wan `monoclonal antibody` tayp ` kemotherapy` dכg we de εp fכ pwεl di kεnsar sεl dεm . Fɔ tɔk am simpul wan, dɛn mek dis mɛrɛsin fɔ fɛn ɛn atak di kansa sɛl dɛn nɔmɔ we de na wi bɔdi. I de wok lɛk mishɔl we de go stret to di say we dɛn want fɔ go. Dis kin ɛp fɔ ridyus di damej we di sɛl dɛn we gɛt wɛlbɔdi kin gɛt.

Wetin na di brand nem fɔ dis mɛrɛsin?

Dɛn kin sɛl dis mɛrɛsin ɔnda di nem `BESPONSA` . Bɔt ivin if yu dɔktɔ nɔ tɛl yu dis nem, di mɛrɛsin gɛt di sem aktif ingridiɛnt `Inotuzumab Ozogamicin`.

Tin dɛm wae yu nid fɔ tɛl yu wɛl bɔdi biznɛs tim bifo yu bigin dis mɛrɛsin

Bifo yu bigin fɔ tek Inotuzumab Ozogamicin, sɔm tin dɛn de we yu fɔ tɛl yu dɔktɔ ɛn nɔs dɛn . I bɛtɛ lɛ wi nɔ ayd dɛn tin ya, nɔto so? Bikɔs dis infɔmeshɔn go ɛp yu fɔ gi di tritmɛnt sef wan. Tink bɔt am lɛk fɔ no bifo tɛm bɔt di tin dɛn we go ambɔg yu we yu de na rod. Dɔn wi kin tek tɛm.

So, rili tɔk bɔt dɛn tin ya:

• Yu gɛt at sik ? Sɔntɛm sɔntin lɛk at bit we nɔ de bit ɔltɛm ?
• Ɛni prɔblɛm de wit di liva ( liva sik ) ? Di liva na wan ɔgan we rili impɔtant na wi bɔdi.
• Yu blɔd kɔnt kin smɔl bikɔs ɔf sɔm mɛrɛsin dɛn we yu bin dɔn tek trade.Yu tink se i smɔl? Dat min se wayt blɔd sɛl, rɛd blɔd sɛl, ɛn ɔda tin dɛn.
• Yu nɔ gɛt bɔku kalsiɔm, magnɛsiɔm, ɔ potashɔm ? Dɛn tin ya rili impɔtant fɔ mek wi bɔdi wok.
• Yu dɔn ɛva gɛt alɛji fɔ Inotuzumab Ozogamicin, ɛni ɔda mɛrɛsin, it, day, ɔ prɛzɛvɛtiv? Ɔ yu dɔn ɛva gɛt sɔntin we nɔ kɔmɔn?
• Yu gɛt bɛlɛ naw? Ɔ yu de tray fɔ gɛt bɛlɛ?
• Yu na mama we de gi pikin in bɛlɛ?

If ɛni wan pan dɛn tin ya apin to yu, yu fɔ rili tɛl yu dɔktɔ. Dis rili impɔtant fɔ mek yu sef.

Aw dɛn go gi yu dis mɛrɛsin?

Dɛn kin gi yu dis mɛrɛsin as ``infushɔn'' insay wan vein. Fɔ tɔk am simpul wan, i tan lɛk se dɛn de gi yu salin. Dɛn kin jɔs du dis na ɔspitul ɔ klinik usay dɔktɔ ɔ tren wɛlbɔdi wokman de. Dis nɔto mɛrɛsin we yu kin kɛr go na os.

If yu de gi dis mɛrɛsin to yɔŋ pikin dɛn, yu go nid fɔ tɔk bɔt am wit yu pikin dɛn dɔktɔ ɛn tek spɛshal kia, bikɔs yɔŋ pikin dɛn bɔdi difrɛn frɔm big pipul dɛn.

Wetin fɔ du if yu tek bɔku mɛrɛsin?

Bikɔs dis na ɔspitul mɛrɛsin, nid nɔ de fɔ wɔri bɔt fɔ tek ɔvados bay aksidɛnt. Di mɛdikal tim kin rili tek tɛm wit dis. Bɔt if yu tink se sɔntin dɔn apin, mɛmba fɔ ripɔt am to di imejensi rum ɔ di pɔyzin kɔntrol sɛnta (bɔku tɛm na di ɔspitul imejensi rum na Sri Lanka).

Impɔtant: Dis mɛrɛsin na fɔ yu nɔmɔ. Nɔ mek ɔda pɔsin yuz am, ilɛksɛf dɛn gɛt di sem sayn dɛn we yu gɛt.

Wetin a go du if a mis apɔntinmɛnt fɔ tek mɛrɛsin?

Insay dis tritmɛnt, de dɛn kin de we yu dɔktɔ go tɛl yu fɔ kam insay fɔ yu mɛrɛsin. Yu nid fɔ go pan dɛn de dɛn de jɔs. I nɔ fayn fɔ lɛ yu skip di apɔntinmɛnt dɛn we yu kin gɛt fɔ tek mɛrɛsin. If yu du dat, dat kin afɛkt aw yu tritmɛnt go wok fayn. If yu nɔ ebul fɔ go pan di de dɛn we dɛn dɔn sɛtul, mek shɔ se yu kɔl yu dɔktɔ ɔ pɔsin we de kia fɔ yu wɛlbɔdi biznɛs ɛn tɛl dɛn. Dɔn dɛn go tɛl yu wetin fɔ du nɛks.

Us ɔda mɛrɛsin dɛn kin miks (kɔnflikt) wit dis mɛrɛsin?

Naw lɛ wi luk pan sɔm mɛrɛsin dɛm we nɔ fayn fɔ yuz wit `Inotuzumab Ozogamicin`. Dɛn nɔ fɔ tek dɛn tin ya togɛda fɔ tru:

• `Sisapride`
• `Dronedarɔn`
• `Pimozayd`
• `Tioridazin`

Apat frɔm dat, sɔm ɔda mɛrɛsin dɛn de we kin miks wit Inotuzumab Ozogamicin. Fɔ ɛgzampul:

• כda mεdikeshכn dεm we kin mek di at ritm abnכmal na dεn wan dεm we de prolכng di QT intaval (e.g., dofetilide, ziprasidone). di QT intaval na we dεn de mכsu di ilektrikal aktiviti fכ di at pan ECG. If dis intaval lɔng, i kin afɛkt di at in ritm.

Dis list nɔ kɔmplit, nɔto so? So, tɛl yu dɔktɔ bɔt ɔl di mɛrɛsin dɛn we yu de tek (dɛn prɛskrib, ɔva-di-kɔnta, ɛbul, vaytamɛn, it sɔplɛnt). Yu fɔ tɛl yu dɔktɔ bak if yu de smok, drink rɔm, ɔ yuz drɔgs we nɔ rayt. Sɔm tin kin miks wit yu mɛrɛsin.

Wetin yu fɔ tek tɛm wit we yu de tek dis mɛrɛsin?

We dɛn gi yu dis mɛrɛsin, yu dɔktɔ go tek tɛm wach yu. Dɛn go du tin dɛn bak lɛk blɔd wok we yu de tek dis mɛrɛsin. Dis go chɛk if di mɛrɛsin de wok ɛn if ɛni sayd ɛfɛkt de.

If yu tek dis mɛrɛsin , dat kin mek yu bɔdi nɔ ebul fɔ fɛt sik (immunity). So, if yu gɛt sɔm kayn sik lɛk fiva, kol, kol, trot we de at, ɔ kɔf, nɔ fɔ tek mɛrɛsin fɔ yusɛf. Kɔl yu dɔktɔ ɔ pɔsin we de kia fɔ yu wɛlbɔdi biznɛs wantɛm wantɛm fɔ advays. Tray fɔ de fa frɔm pipul dɛn we sik as yu ebul.

Wan ɔda tin na dat dis mɛrɛsin kin mek yu gɛt mɔ blɔd, ɛn yu kin brus izi wan. If yu notis ɛni blɔd we nɔ kɔmɔn (e.g., blɔd we de kɔmɔt na yu nos, yu mɔt, ɔ yu gɔm, blak stɔl, ɔ rɛd/dak brawn urine), tɛl yu dɔktɔ.

spεshal atεnshכn to bεlε, bεlε εn fεtiliti

Dis na tin we rili impɔtant. Yu nid fɔ mɛmba dis.

• Bɛlɛ: Nɔ gɛt bɛlɛ we yu de tek dis mɛrɛsin, ɛn fɔ at le 8 mɔnt afta yu dɔn stɔp di mɛrɛsin. If yu de tray fɔ gɛt bɛlɛ, ɔ if yu tink se yu go gɛt bɛlɛ, yu fɔ tɛl yu dɔktɔ.
• Man: If man de tek dis mɛrɛsin, i nɔ fɔ bɔn pikin we i de tek di mɛrɛsin ɛn fɔ at le 5 mɔnt afta i dɔn stɔp di mɛrɛsin. Dis mɛrɛsin kin mek di pikin we nɔ bɔn yet gɛt siriɔs sayd ɛfɛkt. Aks yu dɔktɔ ɔ fama fɔ no mɔ.
• Fɔ gi yu pikin in mama in bɛlɛ: Nɔ gi yu pikin in mama in bɛlɛ we yu de tek dis mɛrɛsin ɛn fɔ at le 2 mɔnt afta yu dɔn stɔp di mɛrɛsin.
• Di we aw pɔsin kin bɔn pikin:Dis mεdisin kin afekt yu ebul fכ bכn pikin (fεtiliti). If yu gɛt ɛnitin fɔ wɔri bɔt dis, tɔk to yu dɔktɔ bɔt am.

Wetin na di sayd ɛfɛkt dɛm we dis mɛrɛsin kin gɛt?

Lɛk ɛni mɛrɛsin, Inotuzumab Ozogamicin kin mek sɔm sayd ɛfɛkt. Sɔm pan dɛn fɔ ripɔt to yu dɔktɔ wantɛm wantɛm. Bɔku tɛm, ɔda wan dɛn nɔ kin bi big prɔblɛm, bɔt if dɛn kɔntinyu fɔ du dat, i go fayn fɔ mek yu tɛl yu dɔktɔ . Lɛ wi luk dɛn wan bay wan.

Di sayd ɛfɛkt dɛm we yu fɔ ripɔt to yu dɔktɔ wantɛm wantɛm:

If yu gɛt ɛni wan pan dɛn sik ya, tɛl yu dɔktɔ ɔ pɔsin we de kia fɔ yu wɛlbɔdi biznɛs kwik kwik wan :

• Alɛji: Skin de rɔsh, it ɔ ayv, yu fes, yu lip ɔ yu tɔng de swel.
• Blɔd nɔ bɔku: Dis mɛrɛsin kin mek yu wayt blɔd sɛl dɛn, rɛd blɔd sɛl dɛn, ɛn yu pletlɛt dɛn go dɔŋ. Dis kin mek yu gɛt infɛkshɔn mɔ ɛn mɔ, ɛn i kin mek yu blɔd bak.
• Di sayn dɛm wae de sho se yu gɛt smɔl smɔl rɛd blɔd sɛl dɛm: yu kin fil taya pasmak, yu taya, yu kin fɔdɔm, yu kin fil lɛk yu ed de tɔn, ɛn sɔntɛm yu kin fɔdɔm.
• Sayn dɛm fɔ se yu gɛt di sik: fiva ɔ kol, kɔf, trot we de at, pen ɔ i nɔ izi fɔ pis.
• Sayn dεm fכ lכw pletlεt כ bכdi de bכn: Brus, pinpoint rεd spat dεm na di skin.
• Ɔda sayn dɛn we de sho se pɔsin de blɔd: stɔl we gɛt blɔd ɔ we gɛt tar; urine we gɛt rɛd ɔ dak brawn; blɔd we yu de vɔmit ɔ wan brawn tin we tan lɛk kɔfi grɔn; blɔd we nɔ kɔmɔn frɔm di yay, di gɔm, ɔ di nos.
• Sayn dεm fכ wan denja chenj na di at rεt כ di at ritm prכblεm: chεst pen; diziz we pɔsin kin gɛt; di at de bit fast ɔ i nɔ de bit ɔltɛm; di at we pɔsin kin blo; fil lɛk se yu nɔ gɛt bɛtɛ trɛnk, yu ed nɔ gɛt bɛtɛ trɛnk; i nɔ kin izi fɔ yu fɔ blo.
• Sayn ɛn simptom dɛm fɔ liva injuri: Dak yɔlɔ ɔ brawn urine; fil nɔ fayn, fiva; stɔl dɛn we gɛt pale; i nɔ kin want fɔ it igen; vɔmit; pen na di ɔp rayt bɛlɛ; taya ɔ taya we nɔ kɔmɔn; di yay ɔ di skin we de yɔlɔ.

Sayd ɛfɛkt dɛn we nɔ kin nid dɔktɔ advays (bɔt dɛn fɔ ripɔt to di dɔktɔ if dɛn kɔntinyu fɔ de ɔ we de mɔna yu):

Bɔku tɛm, dɛn tin ya kin stɔp insay sɔm dez. Bɔt if dɛn kɔntinyu fɔ du am, ɔ if dɛn de mɔna yu bɔku, tɛl yu dɔktɔ.

• Obstrukshɔn
• Fil fɔ it
• Rɔnbɛlɛ
• Ed de at
• Bɛlɛ de pen
• We pɔsin taya
• Fɔ vɔmit

Dis list nɔto ɔl di sayd ɛfɛkt dɛn we pɔsin kin gɛt. If yu notis ɛnitin we nɔ kɔmɔn, tɔk to yu dɔktɔ bɔt am. Yu kin want bak fɔ ripɔt di sayd ɛfɛkt dɛn to di FDA (Food and Drug Administration) na 1-800-FDA-1088. (Na Sri Lanka, dɛn kin ripɔt dɛn tin ya tru yu dɔktɔ.)

Aw yu kin kip dis mɛrɛsin?

Dis nɔ go bi prɔblɛm fɔ yu. Bikɔs dɛn kin gi yu dis mɛrɛsin na ɔspitul ɔ klinik, yu nɔ nid fɔ kɛr am go na os ɛn kip am. Di wan dɛn we de wok na di mɛrɛsin go tek kia ɔf am. So nid nɔ de fɔ wɔri se di mɛrɛsin go bad ɔ fɔ go na ɔda pɔsin in an.

Fɔ dɔn, di impɔtant tin dɛn we yu fɔ mɛmba na:

Okay, wi don tok plenti abaut dis drug, Inotuzumab Ozogamicin, no bi so? I at fɔ mɛmba ɔl dis wan tɛm. Bɔt i impɔtant fɔ mɛmba dɛn tin ya:

• Dis na spɛshal mɛrɛsin fɔ mɛn kansa, so i impɔtant fɔ tek di tritmɛnt jɔs lɛk aw di dɔktɔ tɛl yu.
• Mek shɔ se yu tɛl yu dɔktɔ bɔt ɛni ɔda sik we yu gɛt, ɔda mɛrɛsin dɛn we yu de tek, ɛn ɛni alɛji we yu gɛt. Nɔ ayd ɛnitin, ivin di smɔl tin.
• Yu fɔ no bɔt di bad tin dɛn we kin apin to yu. Tɛl yu dɔktɔ wantɛm wantɛm if yu gɛt ɛni sayn, mɔ di sayn dɛn we de sho se yu gɛt infekshɔn, blɔd, ɔ yu liva prɔblɛm.
• Fɔ fala di advays bɔt bɛlɛ, aw fɔ gi pikin in bɛlɛ, ɛn aw fɔ bɔn pikin fayn fayn wan. Dis rili impɔtant fɔ yu ɛn yu pikin we nɔ bɔn yet in sef.
• If yu gɛt ɛni kwɛstyɔn ɔ wɔri bɔt dis mɛrɛsin, nɔ shek fɔ aks yu dɔktɔ, nɔs, ɔ fama. Dɛn de de fɔ ɛp yu.

Mɛmba se, if dɛn tɛl yu bɔt dis mɛrɛsin, dat go ɛp yu fɔ go bifo wit dis tritmɛnt fayn fayn wan. Nɔto yu wan, di mɛdikal tim de wit yu ɔltɛm. I rili impɔtant fɔ mek wi kɔntinyu fɔ gɛt gud padi biznɛs wit dɛn. Wi de wish yu fɔ wɛl kwik kwik wan!

` Inotuzumab Ozogamicin, BESPONSA, lukimiya, Akyu Limfoblastik Lukimia, kansa mɛrɛsin, kemotɛrapi, sayd ɛfɛkt dɛn